The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors

V. E. McGilligan; roisin Mcallister; Melody Chemaly; AJ Bjourson; Aaron Peace

The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors

V. E. McGilligan, roisin Mcallister, Melody Chemaly, AJ Bjourson, Aaron Peace

Research output: Contribution to journal › Literature review › peer-review

280 Downloads (Pure)

Abstract

Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 inflammasome family.

Original language	English
Pages (from-to)	1
Number of pages	7
Journal	Online Journal of Cardiovascular Research
Volume	2
Issue number	3
Early online date	13 Nov 2019
Publication status	Published (in print/issue) - 13 Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

OJCR.MS.ID.000556_final 21 nov

Cite this

@article{34f7d0db4e534208a856fd1a8f95ae71,

title = "The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors",

abstract = "Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 inflammasome family.",

author = "McGilligan, {V. E.} and roisin Mcallister and Melody Chemaly and AJ Bjourson and Aaron Peace",

year = "2019",

month = nov,

day = "13",

language = "English",

volume = "2",

pages = "1",

journal = "Online Journal of Cardiovascular Research",

issn = "2643-6884",

number = "3",

}

TY - JOUR

T1 - The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors

AU - McGilligan, V. E.

AU - Mcallister, roisin

AU - Chemaly, Melody

AU - Bjourson, AJ

AU - Peace, Aaron

PY - 2019/11/13

Y1 - 2019/11/13

N2 - Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 inflammasome family.

AB - Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 inflammasome family.

M3 - Literature review

SN - 2643-6884

VL - 2

SP - 1

JO - Online Journal of Cardiovascular Research

JF - Online Journal of Cardiovascular Research

IS - 3

ER -

The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this